Evidence map›Paper›PMID 37384209›Full record

ArticleCase reports in oncology

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report.

Bunpei Isoda, Masanobu Shiga, Shuya Kandori, Yoshiyuki Nagumo, Takayuki Yoshino, Atsushi Ikeda, Takashi Kawahara, Tomokazu Kimura, Hiromitsu Negoro, Akio Hoshi and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Bunpei IsodaDepartment of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Masanobu ShigaDepartment of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Shuya KandoriDepartment of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Yoshiyuki NagumoDepartment of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Takayuki YoshinoDepartment of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Atsushi IkedaDepartment of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Takashi KawaharaDepartment of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Tomokazu KimuraDepartment of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Hiromitsu NegoroDepartment of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Akio HoshiDepartment of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Bryan J MathisInternational Medical Center, University of Tsukuba Affiliated Hospital, Tsukuba, Ibaraki, Japan.
Hiroyuki NishiyamaDepartment of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
University of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enfortumab vedotin (EV) is an antibody-drug conjugate and a promising agent for metastatic urothelial carcinoma (mUC). However, evaluations in end-stage renal disease patients undergoing hemodialysis are unreported. Here, we report such a case. A 74-year-old woman with mUC, on hemodialysis for complete urinary tract extirpation, was diagnosed with multiple pulmonary metastases after treatment with gemcitabine-carboplatin followed by pembrolizumab. As third-line therapy, she received a standard dose of EV. She achieved complete response after 2 cycles without grade 3 or higher adverse events, demonstrating the utility of EV in this setting.

Indexed as

Enfortumab vedotinHemodialysisMetastatic urothelial carcinoma

Identifiers

PMID37384209
PMCPMC10294212
OpenAlexW4381188166

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.